David Stern has over 30 years of women’s health experience and has devoted the majority of his career to the fertility industry. He has held executive leadership positions and built successful teams while launching numerous products in pharmaceutical and biotech markets world-wide. Currently, David serves as the CEO of Boston IVF, one the largest IVF center networks in the United States with 11 full service IVF centers and over 14 satellite centers nationwide.
David served as CEO of Symbiomix Therapeutics a venture backed biotech company. He led the transition of the company from development stage to commercial launch in the US, prior to its acquisition by Lupin Pharmaceuticals in 2017. He served on the board of California Cryobank and has held executive positions in startup companies in the women’s healthcare market, building commercial teams, developing strategy and expanding scientific partnerships for Celmatix, Ohana and OvaScience.
David was the Senior Vice President and Head of the Global Business Franchise for Fertility at Merck Serono, responsible for the strategic development and growth of the portfolio world-wide. Prior to his global role, he was responsible for the US commercial operations in the Fertility, HIV and Growth Hormone markets. David started his career in women’s health with Organon Pharmaceutics. He has an MBA with a concentration in International Marketing and Management from the F.W. Olin School of Business at Babson College and holds a Bachelors’ degree in Biology from Brandeis University.